Arthrex
Device
Arthrex, Inc.
Total Payments
$230.0M
Transactions
2,601
Doctors
848
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $81.4M | 1,462 | 578 |
| 2023 | $86.4M | 1,131 | 466 |
| 2022 | $30.1M | 4 | 1 |
| 2021 | $32.1M | 4 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $228.3M | 1,145 | 99.3% |
| Unspecified | $1.3M | 200 | 0.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $145,037 | 27 | 0.1% |
| Food and Beverage | $92,036 | 1,113 | 0.0% |
| Consulting Fee | $79,344 | 25 | 0.0% |
| Travel and Lodging | $21,859 | 91 | 0.0% |
Payments by Type
General
$228.6M
2,401 transactions
Research
$1.3M
200 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| ACP Max (AICS/600) | Arthrex, Inc. | $289,724 | 3 |
| Dermal Allograft Augmentation of Large and Massive Rotator Cuff Tears (CuffMend) | Arthrex, Inc. | $98,879 | 0 |
| Bone pathologies resulting from acute or chronic injury treated IntraOsseous BioPlasty | Arthrex, Inc. | $59,299 | 0 |
| Multi-center Meniscal Root Clinical | Arthrex, Inc. | $37,965 | 0 |
| Knee Sports Registry | Arthrex, Inc. | $30,226 | 0 |
| BMA, DBM, and IB on the Outcomes of ACLR in Young Adults with an Accelerated Return to Play Protocol | Arthrex, Inc. | $28,021 | 0 |
| The Anti-inflammatory Effects of Autologous Human Thrombin on Pericytes and Tendon | Arthrex, Inc. | $25,321 | 0 |
| 5-Year Follow-Up Following Primary Hip Arthroscopy in High-Level Adult Athletes | Arthrex, Inc. | $24,195 | 0 |
| US20113 Subacromial Bursa Implantation After RCR A Randomized Controlled Trial (IICS/600) | Arthrex, Inc. | $23,140 | 1 |
| Graft Integration in Labral Reconstruction | Arthrex, Inc. | $21,413 | 0 |
| Outcomes Following Brostrom Repair with InternalBrace Ligament Augmentation versus Brostrom Repair | Arthrex, Inc. | $20,000 | 0 |
| Utilizing AI and ML to Delineate Arthroscopic Structures, Injuries, and Procedures | Arthrex, Inc. | $19,500 | 1 |
| Primary Hip Arthroscopy in Athletes Over the Age of 40 | Arthrex, Inc. | $19,150 | 0 |
| Hip Arthroscopy with Concomitant Periacetabular Osteotomy Outcomes at Minimum 10-Year Follow-Up | Arthrex, Inc. | $15,919 | 0 |
| Endoscopic Tendon Compression Bridge Technique for Repair of Partial-Thickness Gluteus Medius Tears | Arthrex, Inc. | $15,860 | 0 |
| Ten-Year Outcomes Hip Arthroscopy for the Treatment of FAI and Labral Tears in Patients with Obesity | Arthrex, Inc. | $15,106 | 0 |
| Minimum 10-Year Outcomes of Hip Arthroscopy with Retroverted Acetabulum | Arthrex, Inc. | $14,235 | 0 |
| IIRR-01164 Outcomes of the Nanoscopic Partial Meniscectomy Versus Standard | Arthrex, Inc. | $13,750 | 0 |
| 10-Year Arthroscopic Treatment of Hip Labral Tears in Young Adults: A Case Series | Arthrex, Inc. | $13,406 | 0 |
| IIRR-01156 (IICS/100) Labral Tear Repair w/All-Suture Knotless Anchors In Primary Hip Arthroscopy. | Arthrex, Inc. | $13,000 | 0 |
Top Doctors Receiving Payments for Arthrex
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Orthopaedic Surgery | San Antonio, TX | $112.8M | 15 |
| , MD | Sports Medicine | Los Angeles, CA | $14.6M | 10 |
| , MD | Orthopaedic Surgery | Knoxville, TN | $8.1M | 9 |
| , M.D | Sports Medicine | Des Plaines, IL | $6.1M | 8 |
| , MD | Orthopaedic Surgery | Birmingham, AL | $5.8M | 9 |
| , M.D | Sports Medicine | Vail, CO | $5.2M | 9 |
| , MD | Sports Medicine | Birmingham, AL | $5.2M | 9 |
| , M.D | Orthopaedic Surgery | New York, NY | $4.7M | 5 |
| , MD | Orthopaedic Surgery | Phoenix, AZ | $4.2M | 11 |
| , MD | Orthopaedic Surgery | Beachwood, OH | $4.2M | 8 |
| , MD | Orthopaedic Surgery | Medford, OR | $3.7M | 16 |
| , M.D | Orthopaedic Surgery | New York, NY | $3.5M | 9 |
| , MD | Orthopaedic Surgery | Chillicothe, OH | $3.4M | 8 |
| , MD | Sports Medicine | Skokie, IL | $3.2M | 24 |
| , MD | Specialist | Pittsburgh, PA | $2.2M | 9 |
| , MD | Sports Medicine | Miami, FL | $2.2M | 8 |
| , MD | Sports Medicine | Atlanta, GA | $1.9M | 9 |
| Unknown | — | Boston, MA | $1.8M | 203 |
| , MD | Orthopaedic Surgery | Sacramento, CA | $1.7M | 11 |
| , M.D | Foot and Ankle Surgery | Harrison, NY | $1.7M | 10 |
| , M.D | Specialist | Long Beach, CA | $1.4M | 8 |
| , MD | Orthopaedic Surgery | Birmingham, AL | $1.3M | 8 |
| , M.D | Foot and Ankle Surgery | New York, NY | $1.3M | 8 |
| , MD FRCSC | Sports Medicine | Sacramento, CA | $1.3M | 8 |
| , M.D | Orthopaedic Surgery | Bingham Farms, MI | $1.3M | 10 |
Ad
Manufacturing Companies
- Arthrex, Inc. $230.0M
Product Information
- Type Device
- Total Payments $230.0M
- Total Doctors 848
- Transactions 2,601
About Arthrex
Arthrex is a device associated with $230.0M in payments to 848 healthcare providers, recorded across 2,601 transactions in the CMS Open Payments database. The primary manufacturer is Arthrex, Inc..
Payment data is available from 2021 to 2024. In 2024, $81.4M was paid across 1,462 transactions to 578 doctors.
The most common payment nature for Arthrex is "Royalty or License" ($228.3M, 99.3% of total).
Arthrex is associated with 20 research studies, including "ACP Max (AICS/600)" ($289,724).